var data={"title":"Nitroprusside: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitroprusside: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6663?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitroprusside-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitroprusside: Patient drug information&quot;</a> and <a href=\"topic.htm?path=nitroprusside-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitroprusside: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709173\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nitropress: After reconstitution, nitroprusside is not suitable for direct injection. The reconstituted solution must be further diluted in dextrose 5% injection before infusion.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypotension:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside can cause precipitous decreases in blood pressure. In patients not properly monitored, these decreases can lead to irreversible ischemic injuries or death. Use only when available equipment and personnel allow blood pressure to be continuously monitored.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cyanide toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Except when used briefly or at low (less than 2 mcg/kg/min) infusion rates, nitroprusside injection gives rise to important quantities of cyanide ion, which can reach toxic, potentially lethal levels. The usual dose rate is 0.5 to 10 mcg/kg/min, but infusion at the maximum dose rates should never last more than 10 minutes. If blood pressure has not been adequately controlled after 10 minutes of infusion at the maximum rate, terminate administration immediately. Although acid-base balance and venous oxygen concentration should be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202198\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nipride RTU;</li>\n      <li>Nitropress</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12817125\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nipride</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202230\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202200\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute hypertension:</b> Initial: 0.3 to 0.5 mcg/kg/minute; may be titrated by 0.5 mcg/kg/minute every few minutes to achieve desired hemodynamic effect (Rhoney 2009); maximum dose: 10 mcg/kg/minute (for a maximum of 10 minutes). To avoid toxicity, some recommend a maximum dose of 2 mcg/kg/minute (Marik 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute decompensated heart failure:</b> IV: Initial: 5 to 10 <b>mcg/minute</b>; may be titrated rapidly (eg, up to every 5 minutes) to achieve desired hemodynamic effect; usual dosage range: 5 to 300 <b>mcg/minute</b>. Doses &gt;400 <b>mcg/minute</b> are not recommended due to minimal added benefit and increased risk for thiocyanate toxicity (HFSA 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202218\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=nitroprusside-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitroprusside: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute hypertension:</b> Infants, Children and Adolescents: Continuous IV infusion: Initial: 0.3 to 0.5 mcg/kg/minute; may be titrated every few minutes to achieve desired hemodynamic effect; usual dose: 3 to 4 mcg/kg/minute; maximum dose: 10 mcg/kg/minute (Chandar 2012; Hegenbarth 2008; NHBPEP 2004; Park 2014). Doses &ge;1.8 mcg/kg/minute are associated with increased cyanide concentration in pediatric postoperative cardiac surgery patients (Moffett 2008); monitor cyanide levels with prolonged use (eg, &gt;72 hours) (NHBPEP 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202201\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202202\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use in patients with renal impairment may lead to the accumulation of thiocyanate and subsequent toxicity; limit use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Limit mean infusion rate to &lt;3 mcg/kg/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anuric patients: Limit mean infusion rate to 1 mcg/kg/minute.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202203\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling; due to the risk of cyanide toxicity, use with caution.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202177\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nitropress: 25 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nipride RTU: 10 mg/50 mL in NaCl 0.9% (50 mL); 50 mg/100 mL in NaCl 0.9% (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202162\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202182\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: IV infusion only; infusion pump required. Due to potential for excessive hypotension, continuously monitor patient&rsquo;s blood pressure during therapy. Product should always be protected from light, even during administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473001\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 50 mg in 250 mL (concentration: 200 <b>mcg</b>/mL) <b>or</b> 100 mg in 250 mL (concentration: 400 <b>mcg</b>/mL) of D<sub>5</sub>W</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473002\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 100 <b>mcg</b>/mL <b>or</b> 200 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202181\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of hypertensive crises; acute decompensated heart failure (HF); used for controlled hypotension to reduce bleeding during surgery</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469127\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hypertension during acute ischemic stroke</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202238\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nitroprusside may be confused with nitroglycerin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202169\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, ECG changes, flushing, palpitations, severe hypotension, substernal pain, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Apprehension, dizziness, headache, increased intracranial pressure, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, localized erythematous streaking, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, intestinal obstruction, nausea, retching</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased platelet aggregation, methemoglobinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Irritation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle twitching</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202185\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of compensatory hypertension (aortic coarctation, arteriovenous shunting); to produce controlled hypotension during surgery in patients with known inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) requiring emergency surgery; acute heart failure associated with reduced systemic vascular resistance (eg, septic shock); congenital (Leber's) optic atrophy or tobacco amblyopia; concomitant use with sildenafil, tadalafil, vardenafil, or riociguat</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindication (not in US labeling): Hypersensitivity to nitroprusside or any component of the formulation; uncorrected anemia or hypovolemia; hepatic disease; severe renal disease; disease states associated with vitamin B<sub>12</sub> deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202166\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cyanide toxicity: <b>[US Boxed Warning]: Except when used briefly or at low (&lt;2 mcg/kg/minute) infusion rates, nitroprusside gives rise to large cyanide quantities. Do not use the maximum dose for more than 10 minutes; if blood pressure is not controlled by the maximum rate (ie, 10 mcg/kg/minute) after 10 minutes, discontinue infusion. Monitor for cyanide toxicity via acid-base balance and venous oxygen concentration; however, clinicians should note that these indicators may not always reliably indicate cyanide toxicity. </b> Patients at risk of cyanide toxicity include those who are malnourished, have hepatic impairment, or those undergoing cardiopulmonary bypass, or therapeutic hypothermia (Rindone 1992). Discontinue use of nitroprusside if signs and/or symptoms of cyanide toxicity (eg, metabolic acidosis, decreased oxygen saturation, bradycardia, confusion, convulsions) occur. Although not routinely done, sodium thiosulfate has been co-administered with nitroprusside using a 10:1 ratio of sodium thiosulfate to nitroprusside when higher doses of nitroprusside are used (eg, 4 to 10 mcg/kg/minute) for extended periods of time in order to prevent cyanide toxicity (Shulz 2010; Varon 2008); thiocyanate toxicity may still occur with this approach (Rindone 1992). The use of other agents (eg, clevidipine, labetalol, nicardipine) should be considered if blood pressure is not controlled with nitroprusside.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: <b>[US Boxed Warning]: Excessive hypotension resulting in compromised perfusion of vital organs may occur; continuous blood pressure monitoring by experienced personnel is required. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intracranial pressure: Use may elevate intracranial pressure; in patients whose intracranial pressure is already elevated, use only with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methemoglobinemia: Nitroprusside can cause a dose-dependent conversion of hemoglobin to methemoglobin. Methemoglobinemia should be suspected in any patient receiving &gt;10 mg/kg of nitroprusside and exhibiting signs of impaired oxygen delivery despite adequate cardiac output and arterial pO<sub>2</sub>. Symptomatic patients, regardless of methemoglobin level should be treated with methylene blue (first-line). Treatment is suggested if level is &ge;30% even if asymptomatic unless patient has a preexisting condition (eg, coronary artery disease) and are incapable of tolerating reductions in oxygen carrying capacity then treatment is suggested if level reaches 10% (Cortazzo 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thiocyanate toxicity: Can occur in patients with renal impairment or those on prolonged infusions (ie, &gt;3 mcg/kg/minute for &gt;72 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing anemia prior to use when possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia: When nitroprusside is used for controlled hypotension during surgery, correct pre-existing hypovolemia prior to use when possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarction: Use caution in patients with acute myocardial infarction because of hemodynamic effects and possible coronary steal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with extreme caution in patients with renal impairment; use the lowest end of the dosage range; monitor thiocyanate concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: Nitropress: <b>[US Boxed Warning]: Solution must be further diluted with 5% dextrose in water. Do not administer by direct injection.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299769\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202171\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9707&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Nitroprusside.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Nitroprusside.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: May enhance the hypotensive effect of Nitroprusside.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202173\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13263869\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal studies have shown that nitroprusside may cross the placental barrier and result in fetal cyanide levels that are dose-related to maternal nitroprusside levels.  However, information related to use in pregnancy is limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617180\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if nitroprusside is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202175\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure via arterial line and heart rate (cardiac monitor and blood pressure monitor required) (Friedrich 1995); monitor for cyanide and thiocyanate toxicity; monitor venous oxygen saturation; monitor acid-base status as acidosis can be the earliest sign of cyanide toxicity; monitor thiocyanate levels if requiring prolonged infusion (&gt;3 days) or dose &gt;3 mcg/kg/minute or patient has renal dysfunction; monitor cyanide blood levels (if available with appropriate turnaround time) in patients with decreased hepatic function</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202178\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Serum thiocyanate levels are not helpful in detecting toxicity. A level may be confirmatory if a patient is exhibiting signs and symptoms of thiocyanate toxicity. Initial signs of toxicity (eg, tinnitus) may be observed at levels &gt;35 mcg/mL (manufacturer suggests 60 mcg/mL), but serious toxicity typically may not occur with levels &lt;100 mcg/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202165\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Causes peripheral vasodilation by direct action on venous and arteriolar smooth muscle, thus reducing peripheral resistance; will increase cardiac output by decreasing afterload; reduces aortal and left ventricular impedance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202184\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Hypotensive effect: &lt;2 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Hypotensive effect: 1-10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nitroprusside combines with hemoglobin to produce cyanide and cyanmethemoglobin. Cyanide detoxification occurs via rhodanase-mediated conversion of cyanide to thiocyanate; rhodanase couples cyanide molecules to sulfane sulfur groups from a sulfur donor (eg, thiosulfate, cystine, cysteine). This process has limited capacity and may become overwhelmed with large exposures once sulfur donor supplies are exhausted resulting in toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Nitroprusside, circulatory: ~2 minutes; Thiocyanate, elimination: ~3 days (may be doubled or tripled in renal failure) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as thiocyanate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323524\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nipride RTU Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/50 mL 0.9% (50 mL): $48.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/100 mL 0.9% (100 mL): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitropress Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (2 mL): $360.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nitroprusside Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (2 mL): $330.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202187\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Doketrol (AR);</li>\n      <li>Naniprus (PL);</li>\n      <li>Nipride (BE, CH, FR, GB, IE, LU, NL, QA, SA);</li>\n      <li>Niprusodio (UY);</li>\n      <li>Nipruss (DE, EG, JO, LU);</li>\n      <li>Nitan (MX);</li>\n      <li>Nitriate (FR, VN);</li>\n      <li>Nitrocef (BD);</li>\n      <li>Nitroprus (BR);</li>\n      <li>Nitroprusiato de sodio (PE, PY, VE);</li>\n      <li>Nitroprusiato de sodio-ecar (CO);</li>\n      <li>Nitroprussiat Fides (ES);</li>\n      <li>Sodio Nitroprussiato (IT);</li>\n      <li>Sodium Nitroprusside (GB);</li>\n      <li>Sodium Nitroprusside BP (AU);</li>\n      <li>Sonide (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Berlin CM, &ldquo;The Treatment of Cyanide Poisoning in Children,&rdquo; <i>Pediatrics</i>, 1970, 46(5):793-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/4320419/pubmed\" target=\"_blank\" id=\"4320419\">4320419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortazzo JA, Lichtman AD. Methemoglobinemia: a review and recommendations for management. <i>J Cardiothorac Vasc Anesth</i>. 2014;28(4):1043-1047. doi: 10.1053/j.jvca.2013.02.005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/23953868/pubmed\" target=\"_blank\" id=\"23953868\">23953868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chandar J, Zilleruelo G. Hypertensive crisis in children. <i>Pediatr Nephrol</i>. 2012;27( 5 ):741-751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/21773822/pubmed\" target=\"_blank\" id=\"21773822\">21773822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(1):66-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/10669188/pubmed\" target=\"_blank\" id=\"10669188\">10669188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friederich JA, Butterworth JF 4th. Sodium nitroprusside: twenty years and counting. <i>Anesth Analg</i>. 1995;81(1):152-162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/7598246/pubmed\" target=\"_blank\" id=\"7598246\">7598246</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ihlen H, Myhre E, and Opstad P, &ldquo;Evaluation of Potential Adverse Effects of Sodium Nitroprusside During Pacing-Induced Myocardial Ischaemia in Man,&rdquo; <i>Eur Heart J</i>, 1984, 5(10):834-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/6499856/pubmed\" target=\"_blank\" id=\"6499856\">6499856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johanning RJ, Zaske DE, Tschida SJ, et al. A retrospective study of sodium nitroprusside use and assessment of the potential risk of cyanide poisoning. <i>Pharmacotherapy</i>. 1995;15(6):773-777.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/8602386/pubmed\" target=\"_blank\" id=\"8602386\">8602386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE and Varon J. Hypertensive crises: challenges and management. <i>Chest</i>. 2007;131:1949-1962.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/17565029/pubmed\" target=\"_blank\" id=\"17565029\">17565029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moffett BS and Price JF, &quot;Evaluation of Sodium Nitroprusside Toxicity in Pediatric Cardiac Surgical Patients,&quot; <i>Ann Pharmacother</i>, 2008, 42(11):1600-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/18957627/pubmed\" target=\"_blank\" id=\"18957627\">18957627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nipride RTU (sodium nitroprusside) [prescribing information]. Lenoir, NC: Exela Pharma Sciences LLC; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nipride (sodium nitroprusside) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nitropress (sodium nitroprusside) [prescribing information]. Lake Forest, IL: Hospira Inc; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmer RF and Lasseter KC, &ldquo;Drug Therapy: Sodium Nitroprusside,&rdquo; <i>N Engl J Med</i>, 1975, 292(6):294-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/1089194/pubmed\" target=\"_blank\" id=\"1089194\">1089194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhoney D and Peacock WF, &ldquo;Intravenous Therapy for Hypertensive Emergencies, Part 1&rdquo;, <i>Am J Health-Syst Pharm</i>, 2009, 66(15):1343-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/19635770/pubmed\" target=\"_blank\" id=\"19635770\">19635770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rindone JP, Sloane EP. Cyanide toxicity from sodium nitroprusside: risks and management. <i>Ann Pharmacother</i>. 1992;26:515-519.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/1533553/pubmed\" target=\"_blank\" id=\"1533553\">1533553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulz LT, Elder EJ, Jones KJ, et al. Stability of Sodium nitroprusside and sodium thiosulfate 1:10 intravenous admixture. <i>Hosp Pharm</i>. 2010;45(10):779-784.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/21625332/pubmed\" target=\"_blank\" id=\"21625332\">21625332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varon J. Treatment of acute severe hypertension. <i>Drugs</i>. 2008;68(3):283-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/18257607/pubmed\" target=\"_blank\" id=\"18257607\">18257607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vesey CJ and Cole PV, &ldquo;Blood Cyanide and Thiocyanate Concentrations Produced by Long-Term Therapy With Sodium Nitroprusside,&rdquo; <i>Br J Anaesth</i>, 1985, 57(2):148-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/3970795/pubmed\" target=\"_blank\" id=\"3970795\">3970795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wesson DE, Foley R, Sabatini S, et al, &ldquo;Treatment of Acute Cyanide Intoxication With Hemodialysis,&rdquo; <i>Am J Nephrol</i>, 1985, 5(2):121-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/3993700/pubmed\" target=\"_blank\" id=\"3993700\">3993700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitroprusside-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9707 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709173\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202198\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12817125\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F202230\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F202200\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F202218\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F202201\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F202202\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F202203\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202177\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F202162\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F202182\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14473001\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14473002\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F202181\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469127\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F202238\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202169\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202185\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202166\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299769\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202171\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202173\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13263869\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617180\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F202175\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F202178\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202165\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F202184\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323524\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F202187\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9707|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitroprusside-patient-drug-information\" class=\"drug drug_patient\">Nitroprusside: Patient drug information</a></li><li><a href=\"topic.htm?path=nitroprusside-pediatric-drug-information\" class=\"drug drug_pediatric\">Nitroprusside: Pediatric drug information</a></li></ul></div></div>","javascript":null}